Skip to main content

IWANA

Menu

Publications

  1. Byrne S, Baba T, Kawaguchi N, Yamamoto A, Nakano Y, Dorrepaal C, Londt B, Mann A, Veselinski N, Uehara T. Phase 2a randomized placebo-controlled human challenge trial of the RSV L-protein inhibitor S-337395 for respiratory syncytial virus infection. Clinical Infectious Diseases 2026:ciag367. (Epub ahead of print) https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag367/8708081
  2. Piao Y, Kimijima Y; PhRMA Japan Medical Affairs Committee Working Group; Nakamura M, Matsui N. Characteristics and future perspectives of available electronic health record databases in Japan. Drugs Real World Outcomes. 2026 (Epub ahead of print) https://link.springer.com/article/10.1007/s40801-026-00562-w
  3. Takizawa T, Ihara K, Yoshikawa R, Togo K, Kitano T, Iijima M. Clinical and social burden of migraine in Japanese males: a cross-sectional comparison with females without menstrual migraine. The Journal of Headache and Pain. 2026. (Epub ahead of print) https://link.springer.com/article/10.1186/s10194-026-02405-z
  4. Seko Y, Yamaguchi K. Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan. Journal of Gastroenterology. 2026;61(7):880-908. https://link.springer.com/article/10.1007/s00535-026-02401-9
  5. Nawathe V, Verma S, Pal A, Pawar D, Sharma A. A to Z of Health: An evidence-based narrative review of multivitamin-multimineral and nutraceutical supplementation. Cureus. 2026;30;18(4):e108032. https://assets.cureus.com/uploads/review_article/pdf/470482/20260530-216026-3rtx9x.pdf
  6. Koyama T, Shimizu T, Kondo S, Katsuya Y, Sudo K, Yoshida T, Yonemori K, Matsumoto K, Yamamoto N. Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study. BMC Research Notes. 2026;19:203. https://link.springer.com/article/10.1186/s13104-026-07787-6
  7. Thanawala S, Shah R, Alluri KV, Bhupathiraju K, Desomayanandanam P, Bhuvenendran A. Efficacy and safety of Ashwagandha root extract sustained-release (AshwaSR) capsules in healthy adult, stressed subjects: A randomized, double-blind, placebo-controlled, parallel-group, 3-arm clinical trial. Medicine (Baltimore). 2026;105(11):e47990. https://journals.lww.com/md-journal/fulltext/2026/03130/efficacy_and_safety_of_ashwagandha_root_extract.87.aspx
  8. Xu L, Aoyagi SS, Nukui Y, Oguri T, Togo K. Real-world treatment patterns and medical burden in patients with NSCLC: a retrospective database study in Japan. Future Oncology. 2026:1-12. https://www.tandfonline.com/doi/full/10.1080/14796694.2026.2645989
  9. Kessoku T, Higashibata T, Oyamada S, Morioka Y, Koretaka Y, Ichikawa Y, Nakajima A, Hisanaga T. Outcomes in patients with cancer following opioid initiation in Japan: an exploratory study. BMC Research Notes. 2026. https://link.springer.com/article/10.1186/s13104-026-07752-3
  10. Yamaoka K, Hoshi M, Endo Y, Hirano T. Risk factors for major adverse cardiovascular events, malignancies, and serious infections with tofacitinib in rheumatoid arthritis: Post hoc analysis of a 3-year J-post-marketing surveillance. International Journal of Rheumatic Diseases. 2026;29(2):e70572. https://onlinelibrary.wiley.com/doi/10.1111/1756-185x.70572 doi:10.1111/1756-185x.70572
  11. Ebihara K, Hata T, Sato Y, Miyano M. Postmarketing surveillance of the safety and effectiveness of metreleptin in patients with lipodystrophy in Japan. Journal of the Endocrine Society. 2026;10(2):bvaf216. https://academic.oup.com/jes/article/10/2/bvaf216/8402160
  12. Atsumi T, Hanaoka H, Nishijima N, Murakami K, Nio M, Urakawa T, Fujimura T, Hayashi H. Real-world glucocorticoid prescription patterns in patients with lupus nephritis: A retrospective study using a healthcare insurance claims database. Lupus. 2026;35(2):129-139. https://journals.sagepub.com/doi/10.1177/09612033251408515
  13. Takizawa T, Ihara K, Yoshikawa R, Togo K, Kitano T, Iijima M. Clinical characteristics and social burden of menstrual migraine in Japan: an online-based cross-sectional questionnaire study. The Journal of Headache and Pain. 2025;26(1):276. https://link.springer.com/article/10.1186/s10194-025-02219-5
  14. Fujihara K, Sugita C, Yamashita K, Kamei Y. Assessing the benefits of “Circle”: A patient support program for neuromyelitis optica spectrum disorder for patients receiving satralizumab treatment. Clinical and Experimental Neuroimmunology. 2025;00:1–9. https://onlinelibrary.wiley.com/doi/10.1111/cen3.70037.
  15. Murakami M, Okubo Y, Kobayashi S, Kikuta N, Ouchi Y, Shishido K, Terui T. Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68-week randomized Phase 3 trial. Journal of the European Academy of Dermatology and Venereology. 2025;00:1-13. https://onlinelibrary.wiley.com/doi/10.1111/jdv.70156.
  16. Tsuda S, Kunikata H, Hashimoto K, Asano T, Ito A, Kokubun T, Mitsuhide Y, Yasuda M, Nakazawa T. Safety and efficacy of orally administered SJP-0008 in central retinal artery occlusion: a phase IIa randomized clinical trial. Ophthalmology Science. 2025:100965. Article in Press. https://www.ophthalmologyscience.org/article/S2666-9145(25)00263-5/fulltext
  17. Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, Kamei Y, Yamashita K, Nakahara J, Nakashima I, Fujihara K. Safety and effectiveness of Satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: A 30‑month interim analysis of post‑marketing surveillance. Neurology and Therapy. 2025. Epub ahead of print. https://link.springer.com/article/10.1007/s40120-025-00799-7
  18. Matsui T, Kamezaki-Nakagawa A, Hoshi M, Hirano H, Sugiyama N, Hirano T, Enami M, Toyoizumi S, Matsuyama F, Murata T, Urata Y, Kawahata K, Tohma S. Incidence and risk of malignancy in Japanese patients with rheumatoid arthritis in the National Database of Rheumatic Diseases in Japan (NinJa Database). International Journal of Rheumatic Diseases. 2025;28(7):e70363. https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185x.70363.
  19. Fumita S, Imai H, Harada T, Akashi Y, Koretaka Y, Morioka Y, Kizawa Y, Tokoro A. The relationship between opioid dose and opioid-induced constipation in Japanese patients with cancer pain: a post hoc analysis of a prospective observational cohort study. Cureus. 2025;17(7):e87697. https://www.cureus.com/articles/365263-the-relationship-between-opioid-dose-and-opioid-induced-constipation-in-japanese-patients-with-cancer-pain-a-post-hoc-analysis-of-a-prospective-observational-cohort-study#!/
  20. Shimazu Y, Murotani K, Kitabayashi H, Nishio Y. Exploratory analysis of practical predictive indices for the efficacy of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma. Hematological Oncology. 2025;43:e70114. https://onlinelibrary.wiley.com/doi/10.1002/hon.70114
  21. Miyake M, Yonemoto N, Togo K, Xu L, Oguri T, Tanaka M, Hasegawa Y, Izawa Y, Araki K. Deep learning model for natural language to assess effectiveness of patients with non-muscle invasive bladder cancer receiving Intravesical Bacillus Calmette-Guérin Therapy. JCO Clinical Cancer Informatics. 2025;9:e2400249. 87
  22. Takekuma M, Nishio S, Yamaguchi S, Yunokawa M, Nishio H, Nishino K, Kurosaki A, Minobe S, Villacampa G, Oaknin A, Okamoto A. Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc. Journal of Gynecologic Oncology. 2025;36:e116. https://ejgo.org/DOIx.php?id=10.3802/jgo.2025.36.e116
  23. Yoshida M, Taguchi N, Piao Y, Gupta R, Peters J, Abdelghany M, Chiang M, Wang C, Berry M, Yotsuyanagi H. Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: a large-scale data analysis using a Japanese claims database. Journal of Clinical Virology Plus. 2025;5(2):100216. https://www.sciencedirect.com/science/article/pii/S2667038025000158?via%3Dihub
  24. Hashimoto A, Morioka Y, Wada S, Koretaka Y, Sonohata M. Incidence of opioid-induced constipation in non-cancer patients using weak opioids for chronic pain in Japan: a cohort study. Scientific Reports. 2025;15(1):17397. https://www.nature.com/articles/s41598-025-01770-0
  25. Mikami K, Miyajima T, Nishino R, Kawazoe N, Kinoshita Y, Okada T, Fukuju H. Efficacy and safety of SDT-001, a dual-task digital device, in managing attention-deficit/hyperactivity disorder symptoms in children and adolescents: a phase 3, randomized, standard treatment-controlled study. Psychiatry Clinical Neurosciences. 2025;79(8):447-457. https://onlinelibrary.wiley.com/doi/10.1111/pcn.13833?msockid=3475cd8acb696cd4318fde2bcaf86d6e
  26. Mikami K, Miyajima T, Nishino R, Kawazoe N, Ochiai T, Okada T, Fukuju H. Exploratory study of dual‐task digital device in children and adolescents with attention‐deficit/hyperactivity disorder. Psychiatry Clinical Neurosciences Reports. 2025;4(2):e70089. https://onlinelibrary.wiley.com/doi/10.1002/pcn5.70089
  27. Ishiguro N, Morioka I, Nakano T, Manabe A, Kawaguchi K, Tanaka S, Kinoshita M. Clinical and virologic outcomes of baloxavir compared with oseltamivir in pediatric patients with influenza in Japan. Infectious Diseases and Therapy. 2025;14(4):833-846. https://link.springer.com/article/10.1007/s40121-025-01131-4
  28. Pal A, Pawar D, Sharma A. Faropenem for the management of infectious diseases – a systematic review of in vitro susceptibility tests and clinical studies. Journal of Laboratory Physicians. 2025;17:1-17. https://jlabphy.org/faropenem-for-the-management-of-infectious-diseases-a-systematic-review-of-in-vitro-susceptibility-tests-and-clinical-studies/#:~:text=The%20in%20vitro%20studies%20indicated,Bacteroides%20species)%20compared%20to%20amoxicillin%2D
  29. Fujitani M, Lu X, Shinnakasu R, Inoue T, Kidani Y, Seki NM, Ishida S, Mitsuki S, Ishihara T, Aoki M, Suzuki A, Takahashi K, Takayama M, Ota T, Iwata S, Shibata RY, Sonoyama T, Ariyasu M, Kitano A, Terooatea T, Kelly Villa J, Yamashita K, Yamasaki S, Kurosaki T and Omoto S. Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study. Frontiers in Immunology. 2025;16:1550279. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1550279/full
  30. Kasturi S, Singh S, Reddy VK, Pratap V, Masalawala A, Misra AK. One-year clinical outcomes of biodegradable polymer coated everolimus-eluting coronary stent: results from a prospective, open-label, non-randomized study. Indian Journal of Clinical Cardiology. 2025;6(2):181-188. https://journals.sagepub.com/doi/full/10.1177/26324636251321226
  31. Fukuoka H, Endo T, Tsuboi S, Fujio S. Prevalence and risk of complications in untreated patients with adult growth hormone deficiency. Pituitary. 2025;28(2):32. https://link.springer.com/article/10.1007/s11102-025-01500-9
  32. Chandorkar AB, Jhala D. Impact of trimetazidine on major adverse cardiac events in Asian patients with acute myocardial infarction: a systematic review. Asian Journal of Cardiology Research. 2025;8(1):124-132. https://journalajcr.com/index.php/AJCR/article/view/254
  33. Sonohata M, Kitamura M, Hashimoto A, Morioka Y. Prescription pattern of laxatives for opioid-induced constipation in Japanese patients with chronic non-cancer pain: a retrospective cohort study of a health insurance claims database. Cureus 2025;17(1):e78212. https://www.cureus.com/articles/308565-prescription-pattern-of-laxatives-for-opioid-induced-constipation-in-japanese-patients-with-chronic-non-cancer-pain-a-retrospective-cohort-study-of-a-health-insurance-claims-database#!/
  34. Ishibashi T, Tanioka H, Ikehara T, Kezbor S, Sonoyama T. Safety, tolerability, and pharmacokinetics of a novel anti-obesity agent, S-309309, in healthy adults with or without obesity. Clinical Drug Investigation. 2025;45(2):85-99. https://link.springer.com/article/10.1007/s40261-024-01418-3
  35. Miyairi I, Miyazawa S, Takahashi Y, Kojima S, Kitanishi Y, Ogura E. Incidence of severe illness in pediatric influenza outpatients treated with baloxavir or neuraminidase inhibitors. Journal of Infection and Chemotherapy. 2025;31(3):102606. https://www.sciencedirect.com/science/article/pii/S1341321X25000029#ack0010
  36. Yoshida M, Taguchi N, Piao Y, Gupta R, Berry M, Peters J, Abdelghany M, Chiang M, Wang C, Yotsuyanagi H. Treatment pattern and clinical outcomes of remdesivir in hospitalized COVID-19 patients with severe chronic kidney disease: a database analysis of acute care hospitals in Japan. Clinical and Experimental Nephrology. 2025;29(5):624-637. https://link.springer.com/article/10.1007/s10157-024-02609-0
  37. Nakayama T, Xu L, Muramatsu Y. CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan. Future Oncology. 2025;21(3):321-330. https://www.tandfonline.com/doi/citedby/10.1080/14796694.2024.2441649?scroll=top&needAccess=true
  38. Takagi T, Xu L, Hoshi M, Arai S. Identifying risk factors of major adverse cardiac events in patients with ulcerative colitis: a retrospective Japanese claims data analysis. Journal of Gastroenterology and Hepatology. 2025;40(2):421-432. https://onlinelibrary.wiley.com/doi/10.1111/jgh.16831
  39. Tsubouchi K, Arima H, Emoto T, Nakazawa H, Kitano T, Mikami M, Aoyagi C, Matsuzaki H, Tominaga K, Gunge N, Miyazaki T, Okabe Y, Nakamura N, Fukuhara Y, Tachibana M, Nakagawa C, Yamazaki F, Haga N. Clinical features and current pharmacotherapy of OAB in practice: ideal and reality. Advances in Therapy. 2025;42(2):1094-1107. https://link.springer.com/article/10.1007/s12325-024-03070-x
  40. Kessoku T, Akamatsu T, Morioka Y, Yokota T, Kobayashi M, Uchida K, Koretaka Y, Nakajima A. Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials. Japanese Journal of Clinical Oncology. 2025:55(1):40-48. https://academic.oup.com/jjco/advance-article-pdf/doi/10.1093/jjco/hyae135/59482395/hyae135.pdf
  41.  
  42. Yoshida M, Taguchi N, Piao Y, Gupta R, Berry M, Peters J, Abdelghany M, Chiang M, Wang C, Yotsuyanagi H. Treatment pattern and clinical outcomes of remdesivir in hospitalized COVID-19 patients with severe chronic kidney disease: a database analysis of acute care hospitals in Japan. Clin Exp Nephrol. 2024. Online ahead of print. https://link.springer.com/article/10.1007/s10157-024-02609-0
  43. Nakayama T, Xu L, Muramatsu Y. CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan. Future Oncol. 2024 Dec 20. Online ahead of print. https://www.tandfonline.com/doi/citedby/10.1080/14796694.2024.2441649?scroll=top&needAccess=true
  44. Tsubouchi K, Arima H, Emoto T, Nakazawa H, Kitano T, Mikami M, Aoyagi C, Matsuzaki H, Tominaga K, Gunge N, Miyazaki T, Okabe Y, Nakamura N, Fukuhara Y, Tachibana M, Nakagawa C, Yamazaki F, Haga N. Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality. Adv Ther. 2024 Dec 24. Online ahead of print. https://link.springer.com/article/10.1007/s12325-024-03070-x
  45. Takizawa T, Kitano T, Togo K, Yoshikawa R, Iijima M. Clinical practice for migraine treatment and characteristics of medical facilities and physicians treating migraine: Insights from a retrospective cohort study using a Japanese claims database. PLoS ONE. 2024;19(12): e0315610. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0315610
  46. Thanawala S, Abiraamasundari R, Shah R. Comparative Pharmacokinetics of Sustained-Release versus Immediate-Release Melatonin Capsules in Fasting Healthy Adults: A Randomized, Open-Label, Cross-Over Study. Pharmaceutics. 2024 Sep 25;16(10):1248. https://www.mdpi.com/1999-4923/16/10/1248
  47. Goi N, Iwata F, Sugihara Y, Higa S, Chikama T. An Open-Label, Phase III Study to Assess the Efficacy and Safety of Cysteamine Ophthalmic Solution 0.55% in Japanese Cystinosis Patients. Clin Ophthalmol. 2024;18: 3457-3471. https://www.dovepress.com/article/download/97675 
  48. Takagi T, Xu L, Hoshi M, Arai S. Identifying Risk Factors of Major Adverse Cardiac Events in Patients With Ulcerative Colitis: A Retrospective Japanese Claims Data Analysis. J Gastroenterol Hepatol. 2024; Epub ahead of print. https://onlinelibrary.wiley.com/doi/10.1111/jgh.16831
  49. Ota T, Kuratani S, Masaki H, Ishizaki S, Seki H, Takebe T. Impact of chronic constipation symptoms on work productivity and daily activity: a large-scale internet survey. JGH Open. 2024;8:e70042. https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70042
  50. Okubo Y, Kobayashi S, Murakami M, Sano S, Kikuta N, Ouchi Y, Terui T. Authors’ Reply to Wang et al., “Comment on ‘Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial’ “. American Journal of Clinical Dermatology. 2024;25(6):1025-1027. https://link.springer.com/content/pdf/10.1007/s40257-024-00896-7.pdf
  51. Kessoku T, Akamatsu T, Morioka Y, Yokota T, Kobayashi M, Uchida K, Koretaka Y, Nakajima A. Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials. Japanese Journal of Clinical Oncology. 2024:hyae135. https://academic.oup.com/jjco/advance-article-pdf/doi/10.1093/jjco/hyae135/59482395/hyae135.pdf
  52. Kitamura M, Morioka Y, Kobayashi M, Ushida T. A web–based survey on the quality of life of patients with opioid induced constipation using weak opioids in chronic non–cancer musculoskeletal pain in Japan. Pain Research. 2024;39(1): 64-75. https://www.jstage.jst.go.jp/article/pain/39/1/39_64/_pdf/-char/ja
  53. Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, Tsumuraya T, Yamashita K, Nakahara J, Nakashima I, Fujihara K. Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance. Neurology and Therapy. 2024;13(5):1361-1383. https://link.springer.com/content/pdf/10.1007/s40120-024-00640-7.pdf
  54. Moribe T, Xu L, Take K, Yonemoto N, Suzuki K. Real-world treatment trends and triple class exposed status in newly diagnosed multiple myeloma patients in Japan: a retrospective claims database study. PLoS One. 2024;19(9):e0310333. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0310333
  55. Okubo Y, Kobayashi S, Murakami M, Sano S, Kikuta N, Ouchi Y, Terui T. Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial. American Journal of Clinical Dermatology. 2024;25(5):837-847. https://link.springer.com/content/pdf/10.1007/s40257-024-00876-x.pdf
  56. Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, Yoshino T, Kato T, Tsuji A. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC. Med. 2024;5(9):1164-1177.e3. https://www.cell.com/med/fulltext/S2666-6340(24)00216-2
  57. Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast Cancer 2024;31:621-632. https://link.springer.com/content/pdf/10.1007/s12282-024-01575-5.pdf
  58. Matsuyama S, Otsubo T, Nomoto K, Higa S, Takashio O. Prevalence of Generalized Anxiety Disorder in Japan: A General Population Survey. Neuropsychiatric Disease and Treatment. 2024;20:1355-1366. https://www.dovepress.com/article/download/93865
  59. Dinh Thiem V, Van Anh PT, Van Men C, Hung DT, Pollard AJ, Kamitani A, Tada Y, Fukuyama H, Iwasaki Y, Ariyasu M, Sonoyama T. A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial. Vaccine. 2024;42(17):3699-3709. https://www.sciencedirect.com/science/article/pii/S0264410X24005231
  60. LoPresti M, Igarashi A, Sonohara Y, Bowditch S. A quantitative cross-sectional study of the burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy in Japan. Epilepsy and Behavior. 2024;154:109741. https://www.epilepsybehavior.com/article/S1525-5050(24)00122-7/fulltext
  61. Nomoto K, Takashio O, Matsuyama S, Higa S, Otsubo T. Diagnosis and Treatment of Generalized Anxiety Disorder in Japan: Psychiatric Specialist Survey. Neuropsychiatric Disease and Treatment. 2024;20:1001-1010. https://www.dovepress.com/article/download/92633
  62. Iwata S, Pollard AJ, Tada Y, Omoto S, Shibata RY, Igarashi K, Hasegawa T, Ariyasu M, Sonoyama T. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults. Scientific Reports. 2024;14(1):9830. https://www.nature.com/articles/s41598-024-57308-3
  63. Nair T, Ray S, George J, Pande A. Efficacy of Trimetazidine in the Prevention of Contrast-Induced Nephropathy in Patients Undergoing Contrast Coronary Intervention: A Systematic Review and Meta-Analysis (PRISMA). Journal of Clinical Medicine. 2024;13(7):2151. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11012740/pdf/jcm-13-02151.pdf
  64. Goto H, Sugita J, Hasegawa Y, Hayasaka K, Sunagoya K, Hatase R, Nishida M, Ichihashi Y, Odera M, Senjo H, Yokoyama S, Ara T, Shiratori S, Endo T, Hino M, Maeda Y, Sawa M, Sato N, Teshima T. Efficacy and Safety of Single-dose Pegfilgrastim for CD34+ Cell Mobilization in Healthy Volunteers: A Phase 2 Study. Transplantation. 2024;108(4):996-1003. https://pmc.ncbi.nlm.nih.gov/articles/PMC10962423/pdf/tpa-108-996.pdf
  65. Kessoku T, Higashibata T, Morioka Y, Naya N, Koretaka Y, Ichikawa Y, Hisanaga T, Nakajima A. Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain. Cureus. 2024;16(3):e55925. https://pmc.ncbi.nlm.nih.gov/articles/PMC11004843/pdf/cureus-0016-00000055925.pdf
  66. Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N. Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. The Journal of Headache and Pain. 2024;25(1):19. https://thejournalofheadacheandpain.biomedcentral.com/counter/pdf/10.1186/s10194-024-01722-5.pdf
  67. Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, Nio M, Fujihara K. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database. Multiple Sclerosis and Related Disorders. 2024;84:105502. https://www.msard-journal.com/article/S2211-0348(24)00081-6/fulltext
  68. Tahara S, Otsuka F, Endo T. Recognition and Practice of Hypopituitarism After Traumatic Brain Injury and Subarachnoid Hemorrhage in Japan: A Survey. Neurology and Therapy 2024;13(1):39-51. https://link.springer.com/content/pdf/10.1007/s40120-023-00553-x.pdf
  69. Morizane, C., Ueno, M., Ikeda, M. et al. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. BJC Reports 2024;2:Article number 3. https://www.nature.com/articles/s44276-023-00028-4.pdf
  70. Izumi N, Kitta T, Mitsui T. Importance of Regular Examination and Follow-up in Pediatric Patients with Neurogenic Bladder: 24-Month Follow-up Study Using a Japanese Health Insurance Database. Advances in Therapy. 2023;40(12):5519-5535.https://link.springer.com/content/pdf/10.1007/s12325-023-02692-x.pdf
  71. Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations. Clinical Drug Investigation. 2023;43(10):785-797. https://link.springer.com/content/pdf/10.1007/s40261-023-01309-z.pdf
  72. Sato S, Tomitori H, Okawa A, Akano K. Prescription patterns of analgesics in cancer patients with bone metastases in Japan: a retrospective database study. International Journal of Clinical Oncology. 2023;28(9):1227-1235. https://pubmed.ncbi.nlm.nih.gov/37314600/
  73. Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Igarashi K, Ariyasu M. Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan. Vaccine X. 2023;15:100390. https://pmc.ncbi.nlm.nih.gov/articles/PMC10562875/pdf/main.pdf
  74. Igarashi A, Togo K, Kobayashi Y, Kamei K, Yonemoto N, Ishiwada N. Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults. Future Virology. 2023;18(10): 643–657. https://www.tandfonline.com/doi/epdf/10.2217/fvl-2023-0069?needAccess=true
  75. Uchino Y, Uchino M, Mizuno M, Shigeno Y, Furihata K, Shimazaki J.
    Morphological alterations in corneal nerves of patients with dry eye and associated biomarkers. Experimental Eye Research. 2023;230:109438. https://pubmed.ncbi.nlm.nih.gov/36933693/
  76. Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuzaki T, Matsuo Y, Kubota R. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults. Clinical Drug Investigation. 2023;43(5):335-346. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177727/pdf/40261_2023_Article_1265.pdf
  77. Kitta T, Mitsui T, Izumi N. Diagnosis and Treatment of Japanese Children with Neurogenic Bladder: Analysis of Data from a National Health Insurance Database. Journal of Clinical Medicine. 2023;12(9):3191. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179246/pdf/jcm-12-03191.pdf
  78. Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y.
    First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus. 2023;20(2):291-301. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024660/pdf/10388_2022_Article_970.pdf
  79. Sonoyama T, Iwata S, Shinkai M, Iwata-Yoshikawa N, Shiwa-Sudo N, Hemmi T, Ainai A, Nagata N, Matsunaga N, Tada Y, Homma T, Omoto S, Yokokawa Shibata R, Igarashi K, Suzuki T, Hasegawa H, Ariyasu M. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine. 2023;41(11):1834-1847. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755034/pdf/main.pdf
  80. Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R.
    Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. Antimicrobial Agents and Chemotherapy. 2022;66(10):e0063222. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578392/pdf/aac.00632-22.pdf
  81. Miyazawa S, Takazono T, Hosogaya N, Yamamoto K, Watanabe H, Fujiwara M, Fujita S, Mukae H. Comparison of intra-familial transmission of influenza virus from index patients treated with baloxavir marboxil or oseltamivir using an influenza transmission model and a health insurance claims database. Clinical Infectious Diseases. 2022;75(6):927-935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522426/pdf/ciac068.pdf
  82. Sonohata M, Wada S, Koretaka Y, Morioka Y, Mishima H, Mawatari M.
    A Survey of the Incidence of Constipation in Patients with Chronic Non-cancer Pain Using Opioid Analgesics in Japan. Pain and Therapy. 2022;11(3):845-859. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314494/pdf/40122_2022_Article_392.pdf
  83. Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M. Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 2022;40(32):4328-4333. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212435/pdf/main.pdf
  84. Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, Igarashi K, Ariyasu M.
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 2022;40(27):3721-3726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122779/pdf/main.pdf
  85. Takeuchi Y, Saito H, Makishima M, Yokoyama H, Yamaguchi T, Fujii H, Inoue E, Isemura T, Kondo S. Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study. Journal of Bone and Mineral Metabolism. 2022;40(2):275-291. https://pubmed.ncbi.nlm.nih.gov/35041084/
  86. Meng F, Li W, Zhi F, Li Z, Xue Z, He S, Chen W, Chen Y, Xing X, Yao C, Wu Y, Zhang S.
    Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study. Digestive Endoscopy. 2021;33(7):1110-1119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596731/pdf/DEN-33-1110.pdf